Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Balcer, Laura J.; Galetta, Steven; Calabresi, Peter A.; Confavreux, Christian; Giovannoni, Gavin; Havrdová, Eva; Hutchinson, Michael; Kappos, Ludwig; Lublin, Fred; Miller, D. H.; O’Connor, PW; Phillips, J. Theodore; Polman, Chris H.; Radüe, Ernst Wilhelm; Rudick, RA; Stuart, William H.; Wajgt, A; Weinstock‐Guttman, Bianca; Wynn, Daniel; Lynn, F; Panzara, Michael A.

doi:10.1212/01.wnl.0000259521.14704.a8

Cited by 119 publications

(116 citation statements)

References 31 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…In the SENTINEL trial, the combination of natalizumab plus IFN-b-1a (natalizumab: 300 mg, intravenous infusion, once every 4 weeks; IFN-b-1a 30 mg, intramuscular injection, once weekly) was compared with placebo plus IFN-b-1a [Rudick et al 2006]. Both trials demonstrated the efficacy of natalizumab treatment in reducing relapse rate, visual loss, disease progression and occurrence of new magnetic resonance imaging (MRI) lesions in MS [Radue et al 2010;Havrdova et al 2009;Balcer et al 2007;Miller et al 2007]. …”

Section: Safety and Efficacymentioning

confidence: 99%

Natalizumab in pediatric multiple sclerosis patients

Yeh

Weinstock‐Guttman

2010

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Pediatric multiple sclerosis (MS) comprises 25% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associated with a 1 : 1000 risk for progressive multifocal leukoencephalopathy (PML), has been shown to be well tolerated in the adult population and may lead to disease remission in adults with highly active disease. Reports of use of this therapy in the pediatric population with highly active disease have been published. This paper reviews current experience with the use of natalizumab in the pediatric MS population, with attention to potential risks and possible long-term outcomes in this population.

show abstract

Section: Safety and Efficacymentioning

confidence: 99%

Natalizumab in pediatric multiple sclerosis patients

Yeh

Weinstock‐Guttman

2010

Ther Adv Neurol Disord

View full text Add to dashboard Cite

show abstract

“…The large phase 3 trial of natalizumab versus placebo also identified a better outcome for natalizumab-treated patients in terms of visual function [18] and health-related quality of life [19].…”

Section: Clinical Efficacymentioning

confidence: 97%

Natalizumab Therapy for Multiple Sclerosis

Chataway

Miller

2013

Neurotherapeutics

View full text Add to dashboard Cite

The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.

show abstract

“…Natalizumab was initially approved for the treatment of relapsing multiple sclerosis (MS) [15][16][17][18] ; however, the drug was later removed from the market after 3 cases of progressive multifocal leukoencephalopathy (PML), a serious infection of the central nervous system caused by the John Cunningham (JC) virus, occurred [19,20] . The efficacy of natalizumab for induction and maintenance of remission in moderate to severely active CD was established in several randomized clinical trials [21] , including ENACT [22] and ENCORE [23] .…”

Section: Anti-integrinsmentioning

confidence: 99%

Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?

Khanna

Mosli²,

Feagan³

2016

Dig Dis

View full text Add to dashboard Cite

Background: Inflammatory bowel diseases (IBD) are a group of heterogeneous conditions, characterized by immune-mediated inflammation of the gastrointestinal tract. Traditionally, medical management of these disorders has been based on use of systemic immunosuppressives. The development of new drugs that selectively inhibit leukocyte trafficking to the gut has the potential to reduce inflammation and minimize systemic toxicities. Key Messages: In this article, we review the immunology of the gut and the mechanism of action these emerging therapies for IBD. Natalizumab, a monoclonal antibody to the α4 integrin, was approved for the treatment of multiple sclerosis and showed promise in Crohn's disease (CD), however it is encumbered by the risk of progressive multifocal leukoencephalopathy. Vedolizumab inhibits the α4β7 integrin to induce clinical remission in patients with both ulcerative colitis and CD. Long-term safety data on this agent is not yet available. We also review agents in the pipeline. Finally, we discuss the positioning of therapies and potential alterations to therapeutic algorithms as new medications emerge. Conclusions: New therapies are emerging for IBD; however, long-term data are pending. The positioning of these agents in algorithms will evolve.

show abstract

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

Abstract: Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Low-contrast acuity testing has the capacity to demonstrate treatment effects and is a strong candidate for assessment of visual outcomes in future multiple sclerosis trials.

Cited by 119 publications

References 31 publications

Natalizumab in pediatric multiple sclerosis patients

Natalizumab in pediatric multiple sclerosis patients

Natalizumab Therapy for Multiple Sclerosis

Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?

Contact Info

Product

Resources

About